home / stock / igc / igc news

IGC News and Press, IGC Pharma Inc.

Stock Information
Company Name: IGC Pharma Inc.
Stock Symbol: IGC
Market: NYSE
Website: igcpharma.com
Menu
Get IGC Alerts

News, Short Squeeze, Breakout and More Instantly...
IGC - IGC Pharma Reaches Previously Disclosed 146-Patient Enrollment Target in Phase 2 CALMA Trial, Advancing Toward Topline Analysis

Company Continuing Limited Over-Enrollment Activities to Account for Attrition and Support Robust Modified Intent-to-Treat, End-of-Treatment and Exploratory Analyses POTOMAC, MD / ACCESS Newswire / June 11, 2026 / IGC Pharma, Inc. (NYSE American:IGC) ("IGC" or the "Company") today announc...
IGC - Ascendiant Capital Markets Raises IGC Pharma Price Target to $5.50, Citing Clinical Progress and 2026 Catalysts

POTOMAC, MD / ACCESS Newswire / June 9, 2026 / IGC Pharma, Inc. (NYSE American:IGC) ("IGC" or the "Company"), a clinical-stage biotechnology company developing therapeutics for Alzheimer's disease, today announced that Ascendiant Capital Markets has issued an updated equity research report on ...

IGC - IGC Pharma Adds Mount Sinai Clinical Site as CALMA Trial Advances Toward Completion and Topline Analysis

Approximately 80% of target participants have completed trial participation, strengthening momentum toward database lock and topline analysis POTOMAC, MD / ACCESS Newswire / June 2, 2026 / IGC Pharma, Inc. (NYSE American:IGC) ("IGC" or the "Company") , a clinical-stage biotechnology comp...

IGC - IGC Pharma GAAP EPS of -$0.02 in-line, revenue of $0.32M beats by $0.09M

2026-05-19 17:32:03 ET More on IGC Pharma Seeking Alpha’s Quant Rating on IGC Pharma Historical earnings data for IGC Pharma Financial information for IGC Pharma Read the full article on Seeking Alpha For further details see: IGC Pharma GAA...
IGC - IGC Pharma Reports First Quarter 2026 Financial Results with CALMA Phase 2 in the final stage, with 80% Enrollment

- Continued Advancement of CALMA Phase 2 Trial - POTOMAC, MD / ACCESS Newswire / May 19, 2026 / IGC Pharma, Inc. (NYSE American:IGC) ("IGC" or the "Company") , a clinical-stage biotechnology company developing therapeutics and artificial intelligence ("AI-enabled") tools for Alzheimer's ...

IGC - IGC Pharma to Present Tau-PET Biomarker Research at 2026 Global Tau Conference

Research highlights advanced imaging analytics that may support Alzheimer's disease monitoring, patient stratification, and future therapeutic development. POTOMAC, MD / ACCESS Newswire / May 15, 2026 / IGC Pharma, Inc. (NYSE American:IGC) ("IGC" or the "Company") , a clinical-stage biot...

IGC - IGC Pharma Advances Caregiver Engagement as Phase 2 CALMA Trial Advances Final Enrollment Phase

Outreach initiative supports awareness of agitation and patient engagement as enrollment approaches completion POTOMAC, MD / ACCESS Newswire / April 28, 2026 / IGC Pharma, Inc. (NYSE American:IGC) ("IGC" or the "Company") , a clinical-stage biotechnology company developing therapeutics f...
IGC - IGC Pharma Adds Kerwin Medical Center in Dallas to Phase 2 CALMA Trial as Enrollment Advances Toward Completion

Behavioral neurology expertise and expanded patient access support final phase of recruitment in Alzheimer's agitation study POTOMAC, MD / ACCESS Newswire / April 22, 2026 / IGC Pharma, Inc. (NYSE American:IGC) ("IGC" or the "Company"), a clinical-stage biotechnology company developing th...

IGC - IGC Pharma Secures Psilocybin Research Authorization, Expanding Focus on Neuropsychiatric Symptoms in Dementia

Authorization provides regulated capability to evaluate emerging therapeutic approaches alongside Phase 2 CALMA trial approaching completion POTOMAC, MD / ACCESS Newswire / April 20, 2026 / IGC Pharma, Inc. (NYSE American:IGC) ("IGC" or the "Company"), a clinical-stage biotechnology compa...

IGC - IGC Pharma Reaches 80% Enrollment in Phase 2 CALMA Trial, Entering Final Phase Ahead of Enrollment Completion and Data Readout

POTOMAC, MD / ACCESS Newswire / April 14, 2026 / IGC Pharma, Inc. (NYSE American:IGC) ("IGC" or the "Company") today announced that it has approximately 80% patient enrollment in its Phase 2 CALMA clinical trial evaluating IGC-AD1 for agitation associated with Alzheimer's disease. ...
Next 10